Injectable in situ self-forming mineral-polymer hybrid composition and uses thereof

• US 8,747,899 B2
• Filed: 10/08/2009
• Issued: 06/10/2014
• Est. Priority Date: 12/09/1999
• Status: Expired due to Fees

• Current Assignee: Smith & Nephew Orthopaedics Ag (Smith & Nephew PLC)
• Original Assignee: Piramal Healthcare Limited (Piramal Enterprises Limited)
• Inventors: Chaput, Cyril, Chenite, Abdellatif
• Primary Examiner(s): DICKINSON, PAUL W
• Application Number:
  US12/575,788
• Publication Number:
  US 20100021545A1
• Time in Patent Office: 1,706 Days
• Field of Search: None
• US Class Current: 424/484
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 24/0063 Phosphorus containing materials, e.g. apatite
• CPC Class Codes: A61L 24/0084 containing fillers of phosphorus-containing inorganic compounds, e.g. apatite
• CPC Class Codes: A61L 24/08 Polysaccharides A61L24/043 takes precedence
• CPC Class Codes: A61L 27/20 Polysaccharides
• CPC Class Codes: A61L 27/24 Collagen
• CPC Class Codes: A61L 27/32 Phosphorus-containing materials, e.g. apatite
• CPC Class Codes: A61L 27/425 of phosphorus containing material, e.g. apatite
• CPC Class Codes: A61L 27/52 Hydrogels or hydrocolloids
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Abstract

Self-forming hybrid compositions consisting in admixed liquid and solid components enable the formation of bio-materials. The present invention proposes a) a thermo-sensitive self-forming liquid component, being water-based and containing at least a polycationic polymer such as chitosan, and an organic mono-phosphate source, which is a solution at a pH ranging from 6.5 to 7.4; b) a solid component being mineral and composed of at least one of calcium, fluoride, strontium, carbonate and phosphate salts. Solid mineral salts preferentially have a recognized bioactive potential such as the calcium phosphate salts for bones. Both solid and liquid components are admixed to form an injectable liquid slurry or pre-gelled paste that turn in situ into a hybrid uniform gel-like bio-material.

Claims

1. An in situ self-forming mineral-polymer hybrid composition comprising:

a) a water-based and thermo-gelling liquid component comprising at least one hydrosoluble cationic polymer, one organic mono-phosphate source, and optionally one water-soluble organic mono-sulfonate, mono-sulfate or mono-carboxylate source;

said liquid component having a pH between 6.5 and 7.4; and

b) a water non-soluble solid component comprising at least one of calcium, fluoride, strontium, carbonate and phosphate salts, said solid component having a particle size ranging from 5 to 1000 micrometers,

wherein said composition contains 50% weight to volume or less of the solid component and said liquid component and solid component are admixed together intimately to form a non-hardening thermo-gelling hybrid composition;

said hybrid composition gelling at temperature between 25°

C. and 60°

C., wherein said liquid component forms a homogeneous solid aqueous gel-like material.

2. The composition according to claim 1, wherein said liquid component is prepared from organic and/or inorganic acid.

3. The composition according to claim 1, wherein said polymer is a cationic hydrophilic polysaccharide bearing amino groups, selected from the group consisting of partially-deacetylated chitosans, and pure chitosan.

4. The composition according to claim 1, wherein said polymer is a partially-deacetylated chitosan with a degree of deacetylation between 30 and 99%.

5. The composition according to claim 1, wherein said liquid component comprises a second soluble polymer selected from the group consisting of, cellulosics and synthetic polymers, including collagen, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl propylcellulose, hydroxymethyl propylcellulose, poly(ethyleneoxide), poly(propylene oxide), poly(ethylene glycol), poly(vinyl pyrrolidone)poly(vinyl alcohol), or derivatives thereof, or a mixture thereof.

6. The composition according to claim 1, wherein said organic mono-phosphate, mono-sulfonate, mono-sulfate and mono-carboxylate sources of said liquid component have a basic character and a pKa between 6.0 and 7.4.

7. The composition according to claim 1, wherein said organic mono-phosphate source is selected from the group consisting of Na₂PO₄C₃H₅(OH)₂, Fe₂PO₄C₃H₅(OH)₂, K₂PO₄C₃H₅(OH)₂, MgPO₄C₃H₅(OH)₂, MnPO₄C₃H₅(OH)₂, Ca₂PO₄C₃H₅(OH)₂, Na₂PO₇C₃H₇, Na₂PO₇C₄H₇, K₂PO₇C₄H₇, NaPO₇C₄H₈, K₂PO₇C₄H₈, Na₂PO₈C₅H₉, K₂PO₈C₅H₉, NaPO₈C₅H₁₀, KPO₈C₅H₁₀, Na₂PO₉C₆H₁₁, NaPO₉C₆H₁₂, K₂PO₉C₆H₁₁, KPO₉C₆H₁₂, Na₂PO₈C₆H₁₃, K₂PO₈C₆H₁₃, NaPO₈C₆H₁₄, KPO₈C₆H₁₄, Na₂PO₉C₆H₁₂, K₂PO₉C₆H₁₂, NaPO₉C₆H₁₃, KPO₉C₆H₁₃, Na₂PO₈C₁₀H₁₁, K₂PO₈C₁₀H₁₁, NaPO₈C₁₀H₁₂, KPO₈C₁₀H₁₂ and derivatives, or mixtures thereof.

8. The composition according to claim 1, wherein said organic mono-phosphate source is alpha-glycerophosphate, beta-glycerophosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-phosphate, or fructose-6-phosphate salt, or a mixture thereof.

9. The composition according to claim 1, wherein said organic mono-sulfonate source is selected from the group consisting of N-[carbamoylmethyl]-2-aminoethanesulfonate (ACES),N,N-bis[2-hydroxyethyl]-2-aminoethane-sulfonate (BES), 3-[N,N-bis(2-hydroxyethyl)amino]-2-hydroxypropane-sulfonate (DIPSO), N-[2-hydroxyethyl]piperazine-N′

-propanesulfonate (HEPES), 2-[N-morpholino]ethane-sulfonate (MES), 4-[N-morpholino]-butanesulfonate (MOBS), 3-[N-morpholino]-2-hydroxypropanesulfonate (MOPSO), or N-tris[hydroxymethyl]methyl-2-aminoethanesulfonate (TES), and a mixture thereof.

10. The composition according to claim 1, wherein said liquid component further comprises bis[2-hydroxyethyl]iminotris[hydroxymethyl]methane (BIS-TRIS), or Tris[hydroxymethyl]aminomethane (TRIZMA), or a mixture thereof.

11. The composition according to claim 1, wherein said liquid component further comprises amino-acid residues or sequences, comprising histidine (HIS) or lysine (LYS) residues or sequences.

12. The composition according to claim 1, wherein said liquid component comprises organic polyol ingredient selected from the group consisting of sugar-polyols, saccharide-polyols and glycols, such as glycerol, mannitol, sorbitol, ethylene glycol oligomers, propylene glycol oligomers, fructose, glucose, and maltose.

13. The composition according to claim 1, wherein said liquid component comprises water-soluble phosphate or carbonate salts, or a mixture thereof.

14. The composition according to claim 1, wherein said liquid component has an intrinsic viscosity ranging between 5 and 100,000 mPa·

s at 21°

C.

15. The composition according to claim 1, wherein said solid component comprises calcium phosphate, calcium sulfate, calcium carbonate, calcium titanate, calcium acetate, calcium glycerophosphate, calcium gluconate, calcium propionate compounds or a mixture thereof.

16. The A composition according to claim 1, wherein said solid component comprises at least one calcium phosphate selected from the group consisting of Ca(H₂PO₄)₂.H₂O, CaHPO_4.2H₂O, CaHPO₄, CaZn₃(PO₄)₂, CaZnPO₄, CaNaPO₄, Ca₂PO₄CI, alpha-Ca₃(PO₄)₂, beta-Ca₃(PO₄)₂, Ca₃(PO₄)₂.H₂O, Ca₄(PO₄)₂O, Ca₈H₂(PO₄)_6.5H₂0, Ca₉(HPO₄)(PO₄)₅OH, Ca₁₀(PO₄)₆(OH)_2-2xO_x, and Ca₁₀(PO₄)₆(OH)₂, and derivatives thereof.

17. The composition according to claim 1, wherein said solid component comprises hydroxyapatite and tricalcium phosphate.

18. The composition according to claim 1, wherein said solid component comprises hydroxyapatite and alpha- or beta-tricalcium phosphate, or any combination thereof.

19. The composition according to claim 1, wherein said solid component comprises from 5 to 95% wt. of hydroxyapatite and 90 to 5% wt. of alpha- or beta-tricalcium phosphate.

20. The composition according to claim 1, wherein said solid component comprises from 45-65% wt. of hydroxyapatite and 35-55% wt. of alpha- or beta-tricalcium phosphate.

21. The composition according to claim 1, wherein said solid component comprises natural mineral components including hard-tissue, enamel or dental apatite, coral or nacre.

22. The composition according to claim 1, wherein said solid component comprises additionally a carbonate compound selected from the group consisting of Na₂CO₃, CaCO₃, K₂CO₃, MgCO₃, ZnCO₃, Ca₉K(PO₄)₅(CO₃)₂, Ca_8.5Na_1.5(PO₄)_4.5(CO₃)_2.5, and Ca₉(PO₄)_4.5(CO₃)_1.5.

23. The composition according to claim 1, wherein said solid component comprises additionally a carbonated calcium phosphate.

24. The composition according to claim 1, wherein said solid component comprises additionally a fluoride compound selected from the group consisting of NaF, Na₂Si₆F, KF, KSi₆F, CaF₂, MgF₂, ZnF₂, and sodium fluorophosphates.

25. The composition according to claim 1, wherein said solid component comprises additionally a fluorinated calcium phosphate.

26. The composition according to claim 1, wherein said solid component comprises additionally a strontium compound.

27. The composition according to claim 1, wherein said solid component comprises additionally a strontium containing calcium phosphate.

28. The composition according to claim 1, wherein said solid component comprises natural or synthetic solid components selected from the group consisting of mineral or ceramic materials, bioglasses, polymeric and biopolymeric materials.

29. The composition according to claim 1, wherein said solid component and said liquid component have a solid/liquid weight ratio between 0.05 and 2.0 g/mL.

30. The composition according to claim 1, wherein said hybrid composition of liquid component or solid component is admixed with autologous materials selected from the group consisting of cortical or cortico-cancellous bone, whole blood and blood components, bone marrow, cells isolated from tissues, stroma cells, and hematopoietic cells.

31. The composition according to claim 1, which further comprises osteoinductive agents selected from the group consisting of growth factors, hormones, individual osteoinductive proteins and mixtures of osteoinductive proteins.

32. The composition according to claim 1, which further comprises bone derived materials including demineralized bone matrix (DBM) or powder (DBP).

33. The composition according to claim 1, which further comprises at least one growth factor selected from the group consisting of IGF, EGF, a-FGF, b-FGF, PDGF-A, PDGF-B and TGF-beta.

34. The composition according to claim 1, which further comprises at least one bone morphogenic proteins (BMP), sialoproteins, osteonectin, osteopontin, osteocalcin, calcitonin, or a mixture thereof.

35. The composition according to claim 1, which further comprises anti-resorptive, antibiotic, antiviral, antitumor, and/or immunosuppressive agent.

43. A method of preparation of an in situ self-forming mineral-polymer hybrid composition as described in claim 1 or 36, comprising the step of:

a) preparing a first water-based liquid sub-component comprising at least one hydrosoluble cationic polymer, and preferably at least 0.5% w/v of a chitosan, said first sub-component being stable and stored below 10°

C.;

b) preparing a second water-based liquid sub-component comprising at least one organic mono-phosphate source, and optionally one water-soluble organic mono-sulfonate, mono-sulfate or mono-carboxylate source;

c) preparing a solid component comprising at least one of calcium, fluoride, strontium, carbonate and phosphate salts, such as apatite and one tricalcium phosphate;

d) admixing homogeneously said second liquid sub-component with said solid component into a stable water-based dispersion, said dispersion being stable and stored at room temperature or below; and

e) admixing said first liquid component and said stable dispersion together intimately to form a non-hardening thermo-gelling hybrid composition,

said hybrid composition having a pH between 6.5 and 7.4, being injectable, gelling at the body temperature and being applicable to any defect, cavity or anatomical structure of body'"'"'s tissues.

44. The composition according to claim 1, wherein the liquid component is prepared from an acid selected from the group consisting of malic acid, propionic acid, phosphoric acid, organophosphoric acid, glycerophosphoric acid, lactic acid, hydrochloric acid, ascorbic acid, and acetic acid.

36. An in situ self-forming mineral-polymer hybrid composition comprising:

a) a liquid component, comprising at least 0.5% w/v of a chitosan, 2.0% w/v of a glycerophosphate;

said liquid component having a pH between 6.5 and 7.4; and

b) a solid component comprising at least one apatite and one tricalcium phosphate, said solid component having a particle size ranging from 5 to 1000 micrometers.

37. The composition according to claim 36, wherein said liquid component additionally comprises 0 to 10% w/v of at least one of glycerol, sorbitol, mannitol, ethylene glycol oligomers or polymers, and propylene glycol oligomers or polymers.

38. The composition according to claim 36, wherein said liquid component is admixed with autologous blood, blood component or bone marrow, said autologous blood, blood component or bone marrow being at a concentration ranging from 0 to 25% w/v.

39. The composition according to claim 36, wherein said solid component is a dry mixture of at least hydroxyapatite and beta-tricalcium phosphate.

40. The composition according to claim 36, wherein said solid component additionally comprises at least a strontium containing calcium phosphate.

41. The composition according to claim 36, wherein said solid component additionally comprises 0 to 25% w/v of dry crunched autologous spongy bone.

42. The composition according to claim 36, wherein said solid component additionally comprises 0 to 55% w/v of dry demineralized bone material.